Anagram Therapeutics
Clinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.
About
Anagram Therapeutics is a clinical-stage private biopharmaceutical company focused on improving the lives of individuals suffering from exocrine pancreatic insufficiency (EPI) caused by conditions such as cystic fibrosis, pancreatic cancer, and other related disorders. The company is developing ANG003, an orally delivered recombinant enzyme therapy. Teams look it up for Biotechnology, Pharmaceuticals, Healthcare.
Frequently asked
What does Anagram Therapeutics do?
Anagram Therapeutics is a Biotechnology company that offers Services. Teams look it up for Pharmaceuticals, Healthcare, Biotech. It is based in Natick, Massachusetts, USA and was founded in 2017. Public records show $285M in total funding. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Anagram Therapeutics raised?
Anagram Therapeutics has raised a total of $285M in funding. The most recent round on record is Investment.
Where is Anagram Therapeutics headquartered?
Anagram Therapeutics is headquartered in Natick, Massachusetts, USA.
When was Anagram Therapeutics founded?
Anagram Therapeutics was founded in 2017.
What industry does Anagram Therapeutics operate in?
Anagram Therapeutics operates in Biotechnology, Pharmaceuticals, Healthcare, Biotech, Drug Discovery.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.